Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
Kangji Medical Holdings Limited 康基醫療控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9997)
STRATEGIC COOPERATION AGREEMENT
ENTERED INTO BETWEEN THE COMPANY AND B. BRAUN MEDICAL
This Announcement is made voluntarily by Kangji Medical Holdings Limited (the "Company") to inform the shareholders and potential investors of the Company of the latest development of the Company's business.
The board (the "Board") of directors (the "Directors") of the Company is pleased to announce that on March 27, 2021, Hangzhou Kangji Medical Instrument Ltd. (ψੰਿᔼᐕኜϞࠢʮ ̡) ("Hangzhou Kangji"), a wholly-owned subsidiary of the Company, and B. Braun Medical (Shanghai) International Trading Co., Ltd. (Ԏࣦᔼᐕ€ɪऎყ൱Ϟࠢʮ̡, "B. Braun Medical") entered into a strategic cooperation agreement (the "Cooperation Agreement"). Accordingly, Hangzhou Kangji and B. Braun Medical agreed to cooperate extensively in product development, manufacturing, sales and marketing, and academic promotion.
Pursuant to the terms of the Cooperation Agreement, both parties agreed to (1) cooperate in surgical equipment, minimally invasive surgical instruments and accessories, such as offering more comprehensive products to physicians and patients through product licensing, OEM/ODM and other modes of cooperation; (2) carry out in-depth cooperation in surgical field in the future, with the scope of cooperation including but not limited to joint design and development of new products, custom processing of product samples, technology transfer, joint laboratory construction, project incubation, etc.; and (3) facilitate the registration and marketing of each other's products in selected regions based on our complementary resources.
B. Braun Medical is a subsidiary of B. Braun Group in the PRC. B. Braun Group is one of the world's leading suppliers of professional medical devices, medical products and surgical medical devices. We are a high-tech enterprise specializing in the development, production and sales of minimally invasive surgical instruments and accessories (MISIA).
The Directors are of the view that the establishment of this strategic partnership with B. Braun Medical will further enhance the Company's R&D capability. Meanwhile, in terms of marketing, it will leverage the Company's existing advantages in sales and marketing in China, further enrich the Company's product portfolio, and improve the Company's long-term competitiveness. In addition, in terms of international business, B. Braun Medical's international promotion capability will play an important role in further developing our overseas market, and it is in line with the overall interests of the Company and its shareholders.
To the best of the knowledge and belief of the Board, having made all reasonable enquiries, B. Braun Medical and its ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")).
Shareholders and investors of the Company should note that the transactions contemplated under the Cooperation Agreement remain subject to the entering into of definitive agreements. In the event any definitive agreement is entered into, the Company will comply with the requirements of the Listing Rules in respect thereof and make further announcement(s) as and when appropriate.
Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.
By order of the Board
Kangji Medical Holdings Limited
March 29, 2021
As at the date of this announcement, the Board comprises Mr. ZHONG Ming, Ms. SHENTU Yinguang and Ms. Frances Fang CHOVANEC as executive Directors; Ms. CAI Li and Mr. CHEN Gang as non-executive Directors; and Mr. JIANG Feng, Mr. GUO Jian and Mr. CHEN Weibo as independent non-executive Directors.